A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00071203" target="_blank" >RIV/00216224:14110/13:00071203 - isvavai.cz</a>

Alternative codes found

RIV/65269705:_____/13:#0002114 RIV/00179906:_____/13:10191710 RIV/00023736:_____/13:00010730 RIV/00064165:_____/13:10191710

Result on the web

<a href="http://dx.doi.org/10.1016/j.leukres.2013.07.021" target="_blank" >http://dx.doi.org/10.1016/j.leukres.2013.07.021</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.leukres.2013.07.021" target="_blank" >10.1016/j.leukres.2013.07.021</a>

Result language

angličtina

Original language name

A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes

Original language description

One hundred thirteen patients with myelodysplastic syndromes (MDS) with &lt;10% of bone marrow blasts received either deferiprone in a daily dose of 40-90 mg/kg (48 patients) or deferasirox in a daily dose of 10-40 mg/kg (65 patients). Median duration oftreatment was 10,9 months for deferiprone and 13,7 months for deferasirox. A substantial reduction of iron stores evaluated as a decrease in serum ferritin of more than 50% of pretreatment level was achieved in 18 patients in deferasirox group (27.7%) but not in any patient treated with deferiprone, The incidence of adverse effects (mostly gastrointestinal symptoms) was similar after administration of both the drugs. The symptoms of deferasirox toxicity were mild and mostly transient and no drug related myelosuppresive effect was observed in contrast to deferiprone where agranulocytosis occurred in 4% of patients and the treatment had to be discontinued due to side effects in 20% of patients.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2013

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Leukemia Research

ISSN

0145-2126

e-ISSN

—

Volume of the periodical

37

Issue of the periodical within the volume

12

Country of publishing house

GB - UNITED KINGDOM

Number of pages

4

Pages from-to

1612-1615

UT code for WoS article

000327539700004

EID of the result in the Scopus database

—